Pulmonary arterial hypertension related to HIV: Is inflammation related to IL-6 the cornerstone?;Hypertension artérielle pulmonaire liée à l'infection VIH: de la pression artérielle pulmonaire à l'interleukine-6

Revue de Pneumologie Clinique

Volumn 67, Issue 4, 2011, Pages 250-257

  Tcherakian, C ^a,b   Rivaud, E ^a   Catherinot, E ^a   Zucman, D ^c   Metivier, A C ^a   Couderc, L J ^a,b  

^a FOCH HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Hôpital Foc   (France)

Author keywords

Bosentan; Endothelin; IL 6; Inflammation; PAH; PAH HIV; Pathophysiology

Indexed keywords

ANTIRETROVIRUS AGENT; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 6;

DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOTHELIUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MACROPHAGE; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN-6;

EID: 80052702890     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/j.pneumo.2011.06.006     Document Type: Review

References (62)

1. Kim K.K., Factor S.M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987, 18:1293-1296.
2. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
3. Wagenvoort C.A. Classifying pulmonary vascular disease. Chest 1973, 64:503-504.
4. Mehta N.J., Khan I.A., Mehta R.N., Sepkowitz D.A. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000, 118:1133-1141.
5. Tuder R.M., Groves B., Badesch D.B., Voelkel N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275-285.
6. Dorfmüller P., Perros F., Balabanian K., Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003, 22:358-363.
7. Sitbon O., Lascoux-Combe C., Delfraissy J.F., Yeni P.G., Raffi F., De Zuttere D., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177:108-113.
8. Galiè N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004, 25:2243-2278.
9. Mette S.A., Palevsky H.I., Pietra G.G., Williams T.M., Bruder E., Prestipino A.J., et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992, 145:1196-1200.
10. Humbert M., Monti G., Fartoukh M., Magnan A., Brenot F., Rain B., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998, 11:554-559.
11. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 2008, 22:S41-S47.
12. George M.P., Brower A., Kling H., Shipley T., Kristoff J., Reinhart T.A., et al. Pulmonary vascular lesions are common in SIV- and SHIV-env-infected macaques. AIDS Res Hum Retroviruses 2011, 27:103-111.
13. Ehrenreich H., Rieckmann P., Sinowatz F., Weih K.A., Arthur L.O., Goebel F.D., et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993, 150:4601-4609.
14. Clouse K.A., Cosentino L.M., Weih K.A., Pyle S.W., Robbins P.B., Hochstein H.D., et al. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991, 147:2892-2901.
15. Kanmogne G.D., Primeaux C., Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005, 333:1107-1115.
16. Marecki J.C., Cool C.D., Parr J.E., Beckey V.E., Luciw P.A., Tarantal A.F., et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006, 174:437-445.
17. Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 151:1628-1631.
18. Selimovic N., Bergh C.H., Andersson B., Sakiniene E., Carlsten H., Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009, 34:662-668.
19. Pendergrass S.A., Hayes E., Farina G., Lemaire R., Farber H.W., Whitfield M.L., et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010, 5:e12106.
20. Price L.C., Montani D., Tcherakian C., Dorfmüller P., Souza R., Gambaryan N., et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011, 37:813-822.
21. Steiner M.K., Syrkina O.L., Kolliputi N., Mark E.J., Hales C.A., Waxman A.B. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009, 104:236-244. [28 p following 244].
22. Savale L., Tu L., Rideau D., Izziki M., Maitre B., Adnot S., et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009, 10:6.
23. Karavolias G.K., Georgiadou P., Gkouziouta A., Kariofillis P., Karabela G., Tsiapras D., et al. Short- and long-term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets 2010, 14:1283-1289.
24. Lesprit P., Godeau B., Authier F.J., Soubrier M., Zuber M., Larroche C., et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998, 157:907-911.
25. Jouve P., Humbert M., Chauveheid M.P., Jaïs X., Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 2007, 101:353-355.
26. Rached S., Athanazio R.A., Dias S.A., Jardim C., Souza R. Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome. J Bras Pneumol 2009, 35:804-808.
27. Montani D., Achouh L., Marcelin A.G., Viard J.P., Hermine O., Canioni D., et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 2005, 26:969-972.
28. Yoshio T., Masuyama J.I., Kohda N., Hirata D., Sato H., Iwamoto M., et al. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol 1997, 24:489-495.
29. Jais X., Launay D., Yaici A., Le Pavec J., Tchérakian C., Sitbon O., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58:521-531.
30. Furuya Y., Satoh T., Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010, 7:203-205.
31. Baker J.V., Neuhaus J., Duprez D., Kuller L.H., Tracy R., Belloso W.H., et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011, 56:36-43.
32. Nixon D.E., Landay A.L. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010, 5:498-503.
33. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
34. Rodger A.J., Fox Z., Lundgren J.D., Kuller L.H., Boesecke C., Gey D., et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009, 200:973-983.
35. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
36. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
37. Ehrenreich H., Anderson R.W., Fox C.H., Rieckmann P., Hoffman G.S., Travis W.D., et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990, 172:1741-1748.
38. Cunningham M.E., Huribal M., Bala R.J., McMillen M.A. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997, 25:958-964.
39. McMillen M.A., Huribal M., Cunningham M.E., Kumar R., Sumpio B.E. Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit Care Med 1995, 23:34-40.
40. Rudarakanchana N., Flanagan J.A., Chen H., Upton P.D., Machado R., Patel D., et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002, 11:1517-1525.
41. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 1997, 100:2824-2832.
42. Machado R.D., Eickelberg O., Elliott C.G., Geraci M.W., Hanaoka M., Loyd J.E., et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S32-S42.
43. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K., et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001, 104:790-795.
44. Song Y., Jones J.E., Beppu H., Keaney J......F., Loscalzo J., Zhang Y.Y. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005, 112:553-562.
45. Nunes H., Humbert M., Sitbon O., Morse J.H., Deng Z., Knowles J.A., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003, 167:1433-1439.
46. Caldwell R.L., Lane K.B., Shepherd V.L. HIV-1 Tat interaction with cyclin T1 represses mannose receptor and the bone morphogenetic protein receptor-2 transcription. Arch Biochem Biophys 2006, 449:27-33.
47. Brock M., Trenkmann M., Gay R.E., Michel B.A., Gay S., Fischler M., et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009, 104:1184-1191.
48. Zuber J.P., Calmy A., Evison J.M., Hasse B., Schiffer V., Wagels T., et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004, 38:1178-1185.
49. Morse J.H., Barst R.J., Itescu S., Flaster E.R., Sinha G., Zhang Y., et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996, 153:1299-1301.
50. Degano B., Guillaume M., Savale L., Montani D., Jaïs X., Yaici A., et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010, 24:67-75.
51. Charach G., Grosskopf I., Roth A., Afek A., Wexler D., Sheps D., et al. Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. Am J Cardiol 2011, 107:1353-1356.
52. Miñana G., Núñez J., Sanchis J., Bodí V., Núñez E., Llàcer A. CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 2010, 145:547-548.
53. Uthamalingam S., Patvardhan E.A., Subramanian S., Ahmed W., Martin W., Daley M., et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011, 107:433-438.
54. Acanfora D., Gheorghiade M., Trojano L., Furgi G., Pasini E., Picone C., et al. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J 2001, 142:167-173.
55. Huehnergarth K.V., Mozaffarian D., Sullivan M.D., Crane B.A., Wilkinson C.W., Lawler R.L., et al. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol 2005, 95:1492-1495.
56. Levy W.C., Mozaffarian D., Linker D.T., Sutradhar S.C., Anker S.D., Cropp A.B., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
57. Ommen S.R., Hodge D.O., Rodeheffer R.J., McGregor C.G., Thomson S.P., Gibbons R.J. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation 1998, 97:19-22.
58. Rudiger A., Burckhardt O.A., Harpes P., Müller S.A., Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med 2006, 24:451-454.
59. Degano B., Yaïci A., Le Pavec J., Savale L., Jaïs X., Camara B., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009, 33:92-98.
60. Barnier A., Frachon I., Dewilde J., Gut-Gobert C., Jobic Y., Leroyer C. Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy. Eur Respir J 2009, 34:277-278.
61. Speich R., Jenni R., Opravil M., Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001, 131:663-665.
62. Barbaro G., Lucchini A., Pellicelli A.M., Grisorio B., Giancaspro G., Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006, 92:1164-1166.